

## Références – Gleevec

1. Monographie du Gleevec, 19 septembre 2001 et 7 août 2002.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*, 5 avril 2001;344(14):1031-7.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med* 5 avril 2001;344(14):1038-42.
4. Talpaz M, et al. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase. 42<sup>nd</sup> Annual Meeting of the American Society of Hematology, 1-5 déc. 2000, San Francisco, Ca. (abstract).
5. Kantarjian H, et al. A phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive myeloid leukemia. 42<sup>nd</sup> Annual Meeting of the American Society of Hematology, 1-5 déc. 2000, San Francisco, Ca. (abstract).
6. Sawyers C, et al. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis. 42<sup>nd</sup> Annual Meeting of the American Society of Hematology, 1-5 déc. 2000, San Francisco, Ca.(abstract).
7. Ottmann OG, et al. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias. 42<sup>nd</sup> Annual Meeting of the American Society of Hematology, 1-5 déc. 2000, San Francisco, Ca.(abstract).
8. Mauro MJ, Druker BL. STI571: Targeting BCR-ABL as therapy for CML. *Onco* 2001;6:233-8.
9. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. *Blood* 1<sup>er</sup> oct. 2001;98(7):2039-42.
10. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous Leukemia. *JAMA* 2001;256(8):895-898.
11. CancerNet – Chronic Myelogenous Leukemia. <http://cancernet.nci.nih.gov>
12. Cancer Care Ontario Practice Guidelines Initiative – Drug Therapy for Chronic Myeloid Leukemia (Practice Guideline No 6-3). [http://hiru.mcmaster.ca/ccopgi/guidelines/hem/cpg6\\_3f.html](http://hiru.mcmaster.ca/ccopgi/guidelines/hem/cpg6_3f.html)
13. Kantarjian H, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia *N Enj J Med* 2002; 346(9):645-652.
14. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *NEJM* 2002;347(7):472-80.